Cefpodoxime Dry Syrup Focal D3 Injection: Effects of Cefpodoxime Dry Syrup Focal D3 Injection

Welcome To Plenus Pharmaceuticals (P) Ltd

Plenus Pharmaceuticals is built on its meaning of completeness in pharmaceutical field through our quality healthcare service that leads to healthy life everywhere. It is complete healthcare in every aspect where there is no compromise with quality of products, ensuring full satisfaction to concerned entities.

Cefpodoxime Dry Syrup Focal D3 Injection, a third generation semi-synthetic cephalosporin, exhibits activity against several Gram positive as well as Gram negative microorganisms. This compound is also stable in beta lactamase environment. Cefpodoxime exhibits exceptional activity against methicillin susceptible Staphylococci, Streptococcus pneumonia, Haemophilus influenza, Nesseria spp, and Moxaxella catarrhal, which are referred as the most common hospital acquired and community acquired infections. Clavulanic acid is a natural inhibitor of beta lactamase, which are produced by Streptomycin clavuligerus. It binds to beta lactamase moieties and inactivates them, thus restricting the cefpodoxime destruction. Clavulanic acid has very little antimicrobial activity. Cefpodoxime Dry Syrup Focal D3 Injection pharmacokinetics in cirrhotic patients are similar to those in healthy subjects.

Cefpodoxime Dry Syrup Focal D3 Injection has shown efficacy against most strains of the following microorganisms, both in vitro and in clinical infections. Cefpodoxime exhibits in vitro minimum inhibitory concentrations (MICs) of = 2.0 mcg/mL against most (=90%) of isolates of the following microorganisms. The international clinical experience with this drug has confirmed its efficacy in treating pharyngotonsillitis with 97% to 100% success rates in adults, and 92% to 100% in pediatric patients. Cefpodoxime Dry Syrup Focal D3 Injection has proven efficacious in bronchial infections, and in bacterial pneumonia in lower respiratory tract infections.